NIFTYHEALTHCAREINDEX · NSE
Nifty Healthcare
Index · View only — not on the trading terminal
₹16,613.9
+0.51% (+₹84.75)
Prev. close
₹16,529.15
Volume
3,59,26,512
As of
18 Sept 2026
Price history
Narendra Solanki · Anand Rathi Shares & Stock Brokers · 07 Jan 2026
“Narendra Solanki is constructive on the healthcare sector, particularly hospitals, and anticipates a gradual turnaround in pharma manufacturing. He identifies upcoming GLP-1 patent expiries in early 2026 in major markets like India and Brazil, alongside opportunities in complex generics, as key catalysts for the sector.”
Published mid-session at 09:57 IST. Tracking counts only prices printed after publication — the chart's dashed divider marks that moment; earlier prices never count toward entry or results.
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Index metrics
As of 19 Sept, 06:24 IST
Open
16,547.55
Day High
16,690.4
Day Low
16,545.05
Prev. Close
16,529.15
52W High
16,941.7
52W Low
13,536.5
P/E
43.53
P/B
5.38
Div. Yield
0.46%
Member stocks today
How many of this index's member stocks rose or fell today — a broad move and a few-heavyweights move look very different here.
15
Rose
5
Fell
0
Flat
Composition
20 stocks · 15 advanced · 5 declined
Member stocks, ranked by index weight — heaviest first.
Top weight: SUNPHARMA · 17.1% (free-float mcap share, estimate — not NSE’s published weight)
SUNPHARMA
Sun Pharmaceutical Industries Ltd. · Healthcare
17.1%
₹1,837.3
-1.61%
DIVISLAB
Divi's Laboratories Ltd. · Healthcare
10.5%
₹9,375
+0.56%
APOLLOHOSP
Apollo Hospitals Enterprise Ltd. · Healthcare
8.1%
₹8,944.5
+2.01%
CIPLA
Cipla Ltd. · Healthcare
6.9%
₹1,394.5
+1.32%
MAXHEALTH
Max Healthcare Institute Ltd. · Healthcare
6.9%
₹1,049.3
+1.19%
LAURUSLABS
Laurus Labs Ltd. · Healthcare
6.7%
₹1,954
+0.30%
DRREDDY
Dr. Reddy's Laboratories Ltd. · Healthcare
6.3%
₹1,185
+0.85%
TORNTPHARM
Torrent Pharmaceuticals Ltd. · Healthcare
6.2%
₹4,840
-0.72%
LUPIN
Lupin Ltd. · Healthcare
4.4%
₹2,083
-0.72%
AUROPHARMA
Aurobindo Pharma Ltd. · Healthcare
4.2%
₹1,734
+2.60%
FORTIS
Fortis Healthcare Ltd. · Healthcare
4.1%
₹886
-0.01%
GLENMARK
Glenmark Pharmaceuticals Ltd. · Healthcare
3.2%
₹2,447.4
+1.30%
ALKEM
Alkem Laboratories Ltd. · Healthcare
2.8%
₹5,466.5
+2.21%
ZYDUSLIFE
Zydus Lifesciences Ltd. · Healthcare
2.5%
₹1,160
+2.19%
IPCALAB
Ipca Laboratories Ltd. · Healthcare
2.4%
₹2,009.6
+1.99%
BIOCON
Biocon Ltd. · Healthcare
2.4%
₹385
+1.32%
MANKIND
Mankind Pharma Ltd. · Healthcare
2.3%
₹2,300.7
+0.03%
ABBOTINDIA
Abbott India Ltd. · Healthcare
1.2%
₹27,270
+5.25%
PPLPHARMA
Piramal Pharma Ltd. · Healthcare
1.1%
₹208.16
+1.69%
SYNGENE
Syngene International Ltd. · Healthcare
0.6%
₹369.05
-2.93%
Index levels are informational only, not investment advice.
Abbott India stock rallies as investors respond to strong recent earnings
Abbott India stock rallied over 5% on September 18, 2026, reaching an intraday high of INR 27,490. Investors responded to strong recent earnings, with the company reporting high single-digit revenue growth and double-digit net profit expansion in its latest quarter. The stock outperformed its sector peers, supported by positive technical indicators.
Taro Pharmaceutical Industries stock gains on Sun Pharma merger cash offer
Taro Pharmaceutical Industries stock is gaining as a cash merger with Sun Pharmaceutical Industries is finalized. Shareholders will receive $32.25 per share as of September 17, 2026, converting equity into a fixed cash payout. This move aligns with Sun Pharma's strategy to consolidate subsidiaries and streamline its corporate structure.
Is Laurus (LAURUSLABS.NS) Still a Buy After +2.24% Rally? 2026-09-17 - VOLD Alert
siam.in · 1 day ago
Mankind Pharma Q2 FY27 Earnings Preview
Mankind Pharma's Q2 FY27 earnings date is not yet confirmed, though Indian regulations require results by November 14, 2026. The company's stock traded at Rs 2,250.00 on September 17, 2026, up 0.18%. Investors will compare Q2 FY27 results against Q1 FY27 net profit of Rs 574.00 crore and Q2 FY26 profit of Rs 520.00 crore.
JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?
The Economic Times · 3 days ago
Aurobindo Pharma shares fall 2% after USFDA issues one observation for Telangana facility
Moneycontrol.com · 3 days ago